Combination therapy in hypertension: A focus on angiotensin receptor blockers and calcium channel blockers

American Journal of Therapeutics

Volumn 17, Issue 1, 2010, Pages 61-67

  Meka, Naga ^a   Katragadda, Srikanth ^a   Cherian, Biju ^a   Arora, Rohit R ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Angiotensin receptor blockers; Calcium channel blockers; Hypertension; Myocardial infarction; Stroke

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; GUANABENZ; GUANFACINE; HYDRALAZINE; LABETALOL; LOOP DIURETIC AGENT; LOSARTAN; METHYLDOPA; MINOXIDIL; NIFEDIPINE; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; PRAZOSIN; PROPRANOLOL; TERAZOSIN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT; VERAPAMIL;

ALOPECIA; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ASTHENIA; BLOOD PRESSURE; BRADYCARDIA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRY COUGH; DYSLIPIDEMIA; ECLAMPSIA; EDEMA; ESSENTIAL HYPERTENSION; FATIGUE; FLUID RETENTION; FLUSHING; GLAUCOMA; GYNECOMASTIA; HEART BLOCK; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HIRSUTISM; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTENSION RETINOPATHY; IMPOTENCE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LUPUS LIKE SYNDROME; MIGRAINE; MONOTHERAPY; MORBIDITY; MORTALITY; MUSCLE CRAMP; NEUTROPENIA; OPIATE ADDICTION; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PERIOPERATIVE PERIOD; PERIPHERAL EDEMA; PHARYNGITIS; POSITIONAL DIZZINESS; PREGNANCY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAYNAUD PHENOMENON; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STROKE; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; UNITED STATES;

EID: 76149104308     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31815db6c0     Document Type: Review

References (23)

1. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7 Express). Bethesda, MD: U.S. Department of Health and Human Services; 2003.
2. American Heart Association. Heart disease and stroke statistics: 2004 update. Dallas, TX: American Heart Association; 2003.
3. Ong KL, Cheung BM,Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults, 1999-2004. Hypertension. 2007;49:69-75.
4. Rosamond W, Flegal K, Friday G, et al. For the Committee. A report from the American Heart Association Statistics Committee and Stroke Statistic Subcommittee. Circulation. 2007;115:e69-e171.
5. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
6. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
7. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel blockers: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003;23:2155-2163.
8. Levine CB, Fahrbach KR, Frame D, et al. Effect of amlodipine on systolic blood pressure. Clin Ther. 2003;25:35-57.
9. ö stergren J, Isakssonb H, Brodinc U, et al. For the Study Group. Effect of amlodipine versus felodipine extended release on 24-hour ambulatory blood pressure in hypertension. Am J Hypertens. 1998;11:690-696.
10. Malacco E, Santonastaso M, VarÌ MA, et al. Comparison of valsartan 160 mg with lisinopril 20 mg given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the blood pressure reduction and tolerability in comparison with lisinopril (PREVAIL) study. Clin Ther. 2004;26:855-865. (Pubitemid 38943034)
11. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
12. Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs single-drug therapy of hypertension study: revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens. 1995;8:189-192.
13. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4:393-404.
14. Sica DA. The African American Study of Kidney Disease and Hypertension (AASK). J Clin Hypertens. 2003;5(2): 159-167.
15. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-2816.
16. Dahlof B, Sever PS, Poulter NR, et al. For the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
17. Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep. 2002;4:343-349.
18. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm. 2007;64:1279-1283.
19. Quan A, Chavanu K, Merkel J. A review of the efficacy of fixed-dose combinations of olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. Am J Cardiovasc Drugs. 2006;6: 103-113.
20. Andreadis EA, Tsourous GI, Marakomichelakis GE, et al. High-dose monotherapy vs. low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J Hum Hypertens. 2005;19:491-496.
21. Mistry NB, Westheim AS, Kjeldsen SE. The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Expert Opin Pharmacother. 2006;7:575-581.
22. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Therapeutics. 2007;29:563-580.
23. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens. 2007;9:355-364.